Brief: Opthea Completes Enrollment In Pivotal Phase 3 Clinical Program With Sozinibercept In Wet AMD
28/05/2024 13:28
May 28 (Reuters) - Opthea Ltd OPT.AX :
* OPTHEA COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL
PROGRAM
WITH SOZINIBERCEPT IN WET AMD
* OPTHEA LTD - TOPLINE DATA FROM BOTH PIVOTAL TRIALS
EXPECTED IN
MID-CY2025
Source text for Eikon: ID:nGNXbzqd6c
Further company coverage: OPT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opthea
See all newsBrief: Opthea To Recommence Trading On ASX On Or Around June 3, 2026
Brief: Opthea Says Hamish George Assumes Role Of CFO
Brief: Opthea Logs FY Prelim Loss Attributable $162.8 Mln
Australia's Opthea cuts 80% staff, key executives to exit in deal to avert bankruptcy (updated)
Brief: Opthea Says CEO Fred Guerard To Step Down